vs
NATIONAL BANKSHARES INC（NKSH）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是NATIONAL BANKSHARES INC的2.0倍（$30.3M vs $15.3M），NATIONAL BANKSHARES INC净利率更高（38.5% vs -221.3%，领先259.9%），REGENXBIO Inc.同比增速更快（43.0% vs 24.7%），NATIONAL BANKSHARES INC自由现金流更多（$15.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 20.9%）
尼科特银行股份是一家美国区域性银行控股公司，总部位于威斯康星州格林贝，是尼科特国民银行的母公司，目前是威斯康星州规模第二大的本土银行，深耕当地市场开展各类银行相关金融业务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NKSH vs RGNX — 直观对比
营收规模更大
RGNX
是对方的2.0倍
$15.3M
营收增速更快
RGNX
高出18.3%
24.7%
净利率更高
NKSH
高出259.9%
-221.3%
自由现金流更多
NKSH
多$68.0M
$-52.8M
两年增速更快
RGNX
近两年复合增速
20.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.3M | $30.3M |
| 净利润 | $5.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 47.4% | -190.0% |
| 净利率 | 38.5% | -221.3% |
| 营收同比 | 24.7% | 43.0% |
| 净利润同比 | 91.0% | -31.2% |
| 每股收益（稀释后） | $0.93 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NKSHRGNX
| Q4 25 | $15.3M | $30.3M | ||
| Q3 25 | $14.2M | $29.7M | ||
| Q2 25 | $13.3M | $21.4M | ||
| Q1 25 | $12.8M | $89.0M | ||
| Q4 24 | $12.2M | $21.2M | ||
| Q3 24 | $11.7M | $24.2M | ||
| Q2 24 | $10.9M | $22.3M | ||
| Q1 24 | $10.4M | $15.6M |
净利润NKSHRGNX
| Q4 25 | $5.9M | $-67.1M | ||
| Q3 25 | $4.4M | $-61.9M | ||
| Q2 25 | $2.3M | $-70.9M | ||
| Q1 25 | $3.2M | $6.1M | ||
| Q4 24 | $3.1M | $-51.2M | ||
| Q3 24 | $2.7M | $-59.6M | ||
| Q2 24 | $-307.0K | $-53.0M | ||
| Q1 24 | $2.2M | $-63.3M |
毛利率NKSHRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率NKSHRGNX
| Q4 25 | 47.4% | -190.0% | ||
| Q3 25 | 37.9% | -176.3% | ||
| Q2 25 | 20.0% | -296.3% | ||
| Q1 25 | 30.5% | 13.6% | ||
| Q4 24 | 30.1% | -242.1% | ||
| Q3 24 | 27.5% | -256.6% | ||
| Q2 24 | -4.4% | -251.3% | ||
| Q1 24 | 25.8% | -408.8% |
净利率NKSHRGNX
| Q4 25 | 38.5% | -221.3% | ||
| Q3 25 | 31.1% | -208.3% | ||
| Q2 25 | 17.2% | -331.8% | ||
| Q1 25 | 25.3% | 6.8% | ||
| Q4 24 | 25.1% | -241.3% | ||
| Q3 24 | 22.8% | -246.3% | ||
| Q2 24 | -2.8% | -237.7% | ||
| Q1 24 | 20.8% | -405.4% |
每股收益（稀释后）NKSHRGNX
| Q4 25 | $0.93 | $-1.30 | ||
| Q3 25 | $0.69 | $-1.20 | ||
| Q2 25 | $0.36 | $-1.38 | ||
| Q1 25 | $0.51 | $0.12 | ||
| Q4 24 | $0.50 | $-0.99 | ||
| Q3 24 | $0.42 | $-1.17 | ||
| Q2 24 | $-0.05 | $-1.05 | ||
| Q1 24 | $0.37 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $59.3M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $184.9M | $102.7M |
| 总资产 | $1.8B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NKSHRGNX
| Q4 25 | $59.3M | $230.1M | ||
| Q3 25 | $42.3M | $274.2M | ||
| Q2 25 | $92.8M | $323.3M | ||
| Q1 25 | $122.5M | $267.9M | ||
| Q4 24 | $108.1M | $234.7M | ||
| Q3 24 | $49.8M | $255.5M | ||
| Q2 24 | $98.9M | $290.4M | ||
| Q1 24 | $121.2M | $338.7M |
股东权益NKSHRGNX
| Q4 25 | $184.9M | $102.7M | ||
| Q3 25 | $179.2M | $161.5M | ||
| Q2 25 | $168.7M | $213.7M | ||
| Q1 25 | $167.3M | $274.2M | ||
| Q4 24 | $156.4M | $259.7M | ||
| Q3 24 | $167.8M | $301.4M | ||
| Q2 24 | $149.0M | $348.3M | ||
| Q1 24 | $139.4M | $390.7M |
总资产NKSHRGNX
| Q4 25 | $1.8B | $453.0M | ||
| Q3 25 | $1.8B | $525.2M | ||
| Q2 25 | $1.8B | $581.0M | ||
| Q1 25 | $1.8B | $490.9M | ||
| Q4 24 | $1.8B | $466.0M | ||
| Q3 24 | $1.8B | $519.1M | ||
| Q2 24 | $1.8B | $569.4M | ||
| Q1 24 | $1.7B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $15.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | 99.2% | -174.0% |
| 资本支出强度资本支出/营收 | 17.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.04× | — |
| 过去12个月自由现金流最近4个季度 | $23.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NKSHRGNX
| Q4 25 | $17.9M | $-52.3M | ||
| Q3 25 | $6.1M | $-56.0M | ||
| Q2 25 | $2.1M | $-49.3M | ||
| Q1 25 | $2.6M | $33.6M | ||
| Q4 24 | $9.4M | $-31.6M | ||
| Q3 24 | $3.1M | $-40.5M | ||
| Q2 24 | $-3.0M | $-45.5M | ||
| Q1 24 | $3.8M | $-55.5M |
自由现金流NKSHRGNX
| Q4 25 | $15.2M | $-52.8M | ||
| Q3 25 | $5.3M | $-56.5M | ||
| Q2 25 | $1.5M | $-49.7M | ||
| Q1 25 | $1.6M | $32.6M | ||
| Q4 24 | $6.2M | $-32.7M | ||
| Q3 24 | $2.2M | $-40.9M | ||
| Q2 24 | $-4.0M | $-46.0M | ||
| Q1 24 | $3.5M | $-56.0M |
自由现金流率NKSHRGNX
| Q4 25 | 99.2% | -174.0% | ||
| Q3 25 | 37.4% | -189.9% | ||
| Q2 25 | 11.5% | -232.8% | ||
| Q1 25 | 12.5% | 36.6% | ||
| Q4 24 | 50.5% | -154.2% | ||
| Q3 24 | 18.5% | -168.9% | ||
| Q2 24 | -36.3% | -206.2% | ||
| Q1 24 | 33.8% | -358.5% |
资本支出强度NKSHRGNX
| Q4 25 | 17.9% | 1.7% | ||
| Q3 25 | 5.6% | 1.7% | ||
| Q2 25 | 4.1% | 1.8% | ||
| Q1 25 | 7.5% | 1.2% | ||
| Q4 24 | 26.6% | 5.1% | ||
| Q3 24 | 8.3% | 1.3% | ||
| Q2 24 | 9.3% | 2.1% | ||
| Q1 24 | 3.0% | 3.6% |
现金转化率NKSHRGNX
| Q4 25 | 3.04× | — | ||
| Q3 25 | 1.38× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.79× | 5.53× | ||
| Q4 24 | 3.07× | — | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.77× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NKSH
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
